Corrections Noted in Table 2 of the Study on Ixekizumab and Tirzepatide for Psoriasis in Adults with Overweight or Obesity

To address inaccuracies identified in Table 2 of the original study on Ixekizumab and Tirzepatide.

Correction Details: Baseline PASI was corrected from 'mean (SD)' to 'mean (SE),' and metabolic endpoints were reclassified as 'mean (SE)' to ensure accurate reporting.

Corrections were made to the baseline PASI measurements, which were previously reported inaccurately.
Table 2 contained inaccuracies that have now been rectified.

The article has been rectified online to reflect accurate statistical measures.

Corrections to the baseline PASI and metabolic endpoints have been made to ensure the accuracy of the reported data.